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Integrins are expressed on mast cells and constitute an
essential prerequisite for the accumulation of the cells
at sites of in£ammation. In order to clarify a potential
contribution of in£ammatory cytokines to this process,
we have studied the modulation of integrin expression
and adhesion of immature human mast cells (HMC-1)
to extracellular matrix proteins by interleukin-6, tumor
necrosis factor a, interferon-a and interferon-c. Corti-
costeroids were used for comparison. On £uorescence-
activated cell sorter analysis, preincubation of cells for
48 h with di¡erent concentrations of interleukin-6 in-
duced a signi¢cant, up to 40%, increase of ava5, CD49b
(a2), CD49e (a5), CD49f (a6), and CD51 (av). In contrast,
di¡erent concentrations of tumor necrosis factor a, inter-
feron-a, interferon-c, and dexamethasone (108^1010 M)
inhibited expression of adhesion receptors by up to
60%, reaching signi¢cance for some but not all integ-
rins. On semiquantitative polymerase chain reaction
analysis, interleukin-6, the other cytokines, and corti-
costeroids signi¢cantly modulated expression of a1, av
and a5 integrin chains at mRNA level. Functional sig-
ni¢cance of these ¢ndings was proven in adhesion assays
using ¢bronectin, laminin, and vitronectin, with inter-
leukin-6 causing signi¢cant enhancement of adhesion
in all cases, tumor necrosis factor a and dexamethasone
inducing signi¢cant reduction of adhesion to ¢bronec-
tin and laminin, and interferon-c signi¢cantly inhi-
biting adhesion to ¢bronectin only. Speci¢city of
interleukin-6-induced changes was demonstrated using
antibodies against a1 and a5 integrins in unstimulated
and interleukin-6-prestimulated cells. These data show
that interleukin-6 stimulates mast cell adhesion to ex-
tracellular matrix and thus allows for the accumulation
of the cells at tissue sites by enhancing integrin expres-
sion, whereas tumor necrosis factor a, interferon-a,
interferon-c, and dexamethasone downmodulate this
process. Key words: corticosteroids/¢bronectin/HMC-1 cells/
laminin/vitronectin. J Invest Dermatol 120:795 ^801, 2003
T
here is increasing evidence that adhesive interactions
between mast cells and extracellular matrix (ECM)
proteins play a major role in regulating anchorage,
migration, di¡erentiation, and function of the cells
in various tissues. This concept has received support
by the demonstration of a number of adhesion molecules on rest-
ing and/or activated mast cells (reviewed in Metcalfe et al, 1997;
Henz et al, 2001). Furthermore, there is increasing evidence that
speci¢c molecules orchestrate the expression and function of
these molecules in normal tissue under physiologic conditions
and also in various in£ammatory states where mast cell numbers
are increased (Weber et al, 1995).
Stem cell factor (SCF), one of the major molecules regulating
growth, di¡erentiaton, and function of mast cells, has been
shown to promote adhesion of interleukin-3 (IL-3) dependent
murine bone-marrow-derived mast cells (BMMC) to ¢bronectin
via the integrin receptor very late antigen 5 (Dastych and Met-
calfe, 1994; Kinashi and Springer, 1994). Furthermore, aggregation
of the FceRI and addition of IL-3 have been implicated in adhe-
sion of BMMC to laminin and vitronectin (Thompson et al,
1990; Bianchine et al, 1992). Adhesion of immature human mast
cells (HMC-1) to vitronectin and collagen IV was observed only
after preactivation of cells using the protein kinase activator phor-
bol myristate acetate (PMA) (Krˇger-Krasagakes et al, 1996).
This study was aimed at shedding more light on in£amma-
tion-associated tissue mast cell accumulation by investigating se-
lected pleiotropic proin£ammatory cytokines, compared to anti-
in£ammatory corticosteroids, for their potential e¡ects on ECM
adhesion molecules. HMC-1 cells were chosen as a representative
model for immature human mast cells as only immature mast
cells move into tissue from the blood, and mature mast cells are
never found in the circulation. Like mature human mast cells,
HMC-1 cells have been reported to express CD29 (a1 integrin),
CD 49c (a3a1), CD49d (a4a1), CD49e (a5a1), CD51 (ava1), and
CD61 (a3 integrin) (Guo et al, 1992; Sperr et al, 1992; Columbo
et al, 1995; Shimuzu et al, 1995; Wimazal et al, 1999) and, in addi-
tion, we have also demonstrated CD49b (a2a1) and CD49f (a6a1)
on HMC-1 cells (Krˇger-Krasagakes et al, 1996), possibly as a sign
of their immaturity.
The data obtained show distinctly divergent e¡ects of the cyto-
kines and corticosteroids on HMC-1 cells regarding both integrin
expression and adhesion to ECM, with IL-6 being the only mole-
cule to cause stimulatory e¡ects, suggesting a hitherto unknown
regulatory scheme for mast cell interactions with the ECM.
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MATERIALS AND METHODS
Cell culture and treatment HMC-1, an immature human mast cell
line (kindly provided by J.H. Butter¢eld, Minneapolis, MN), was
maintained in Iscove’s medium, supplemented with 10% fetal bovine
serum, 2 mM glutamine, penicillin/streptomycin (all from Seromed,
Berlin, Germany), and 105 M monothioglycerol (Sigma, Deisenhofen,
Germany), as originally described (Butter¢eld et al, 1988).
HMC-1 cells were treated for 48 h in Iscove’s medium supplemented
with fetal bovine serum (see above) alone, or with human rh IL-6 (10,
100, and 1000 U per ml; CLB, Amsterdam, The Netherlands), tumor
necrosis factor a (TNF-a) (0.6, 1.5, and 3.0 ng per ml; Genzyme,
Cambridge, MA), interferon-a (IFN-a) (10, 100, and 1000 U per ml;
Pepro Tech EC, London, U.K.), or IFN-g (10, 100, and 1000 U per ml;
Genzyme), all dissolved in phosphate-bu¡ered saline (PBS) containing
0.1% bovine serum albumin (BSA). Hydrocortisone (108, 107, and
106 M; Sigma) and dexamethasone (1010, 109, and 108 M; Sigma)
were dissolved in a stock solution of distilled water.
Adhesion assay Flat-bottomed wells in microtiter plates were coated
overnight with 100 ml of appropriate dilutions of either human
vitronectin or human laminin (both from Gibco, Deisenhofen,
Germany), and human ¢bronectin (Boehringer, Mannheim, Germany),
dissolved in PBS (containing Ca2þ/Mg2þ ). Plates were rinsed with this
same bu¡er, and binding sites were blocked by incubation with 100 ml of
PBS/3% BSA for 1 h at 371C. The plates were rinsed again, and after a
washing step with PBS without Ca2þ/Mg2þ , a total of 4104 HMC-1
cells treated for 48 h with TNF-a (1.5 ng per ml), IL-6, IFN-g, IFN-a (all
at 100 U per ml), hydrocortisone (109 M), or dexamethasone (107 M), or
left untreated, were seeded in triplicate in 100 ml serum-free Iscove’s
medium/1% BSA. In order to determine nonspeci¢c binding, cells were
also added to wells that had been coated with PBS/3% BSA alone.
Unbound cells were removed by two gentle washes with PBS. Attached
cells were quanti¢ed photometrically at 405 nm by reference to a standard
curve for HMC-1 cell suspensions, as described before (Krˇger-Krasagakes
et al, 1996). The e¡ect of cytokines and corticosteroids on adhesion of
HMC-1 cells to the various ECM proteins was given as percentage of
change of the adhesion rates in comparison to untreated control cells. Cell
attachment to BSA-coated wells was always less than 5%. Speci¢c binding
to the integrin receptors was determined in IL-6-treated and untreated
HMC-1 cells by preincubation for 30 min with blocking antibodies
against a5 (P1D6), avb5 (P1F6), and the b1 integrin chain (4B4) (Biomol,
Hamburg, Germany) before starting the adhesion assay. For further
details, see Krˇger-Krasagakes et al (1996).
Flow cytometric analysis HMC-1 cells were analyzed for changes in
expression of adhesion receptors by indirect immuno£uorescence and
£ow cytometry, as described before (Krˇger-Krasagakes et al, 1996). Cells
were analyzed using monoclonal antibodies against the following
molecules: CD29 (b1) (K20), CD49a (a1) (HP2B6), CD49b (a2) (Gi9),
CD49c (a3) (M-KID2), CD49d (a4) (HP2/1), CD49e (a5) (SAM1), CD49f
(a6) (GoH3), CD51 (av) (AMF7), and the respective mouse IgG1, IgG2a,
IgG2b, and rat IgG2a isotype controls (all from Immunotech, Hamburg,
Germany), and avb5 (P1F6) (Biomol, Hamburg, Germany). TNF-a and
IL-6 receptor expression on HMC-1 cells was determined using the
following antibodies: CD120a (1680.1), CD120b (22221.3) (both from
R&D Systems,Wiesbaden, Germany), CD126 (B-R6), and CD130 (B-R3)
(both from Biosource, Ratingen, Germany), as described above. Cells were
labeled with DTAF-conjugated F(ab)2 fragments of goat antimouse IgG or
goat antirat IgG, respectively. Gating was only performed in the FSC versus
SSC dotblot, in order to exclude cell debris. In this way, HMC-1 cells were
detectable as a homogeneous cell population. At least 10,000 gated cells
were analyzed. In order to discriminate between positive and negative
cells, isotype- and species-speci¢c control antibodies were used. In the
corresponding £uorescence histograms, positive marker regions were
de¢ned that allowed for the calculation of percent positive cells. When
cytokine-treated and untreated cells were compared, the percentage
change in mean £uorescent signal intensity was calculated.
Reverse transcription polymerase chain reaction (RT-PCR) RT-
PCRwas performed as described before in detail (Krˇger-Krasagakes et al,
1999). Brie£y, total cellular RNA (3 mg per ml), puri¢ed by the guanidium
thiocyanate/cesium chloride method, was transcribed into cDNA using
random priming and ampli¢ed during 30^35 cycles, using integrin- and
receptor-speci¢c oligonucleotide primers. For comparison of integrin
mRNA levels in di¡erent samples, cDNAs were ¢rst adjusted to equal
concentrations of b-actin control fragment (data not shown). To control
for contamination, the PCR mixture was ampli¢ed without cDNA
(water control). Densitometric analysis of the bands obtained from the
ampli¢cation of integrin mRNA was performed and results are given as
optical density values minus background values. The following
oligonucleotides were used: b-actin sense 50 -GTG GGG CGC CCC AGG
CAC CA-30, b-actin antisense 50 -CTC CTT AAT GTC ACG CAC GAT
TTC-30 (540 bp) (Yamamura et al, 1991); a1 integrin sense 50 -ACA GCG
AAG AAC CTC CTG AA-30, a1 integrin antisense 50 -CAG AAT TGT
GCC TCG TTT GA-30 (407 bp); a2 integrin sense 50 -GTG CCT TTG
GAC AAG TGG TT-30, a2 integrin antisense 50 -GGG CAA CTC TGT
GCT TGA TT-30 (298 bp); a3 integrin sense 50 -GCC TGC CAA GCT
AAT GAG AC-30, a3 integrin antisense 50 -CTG ACT TCG TAG GGC
CAC TC-30 (398 bp); a4 integrin sense 50 -TTC GGA GCC AGC ATA
CTA CC-30, a4 integrin antisense 50 -ACG AGG TTT GTT TCC ATT
GC-30 (298 bp); a6 integrin sense 50 -GGA ATC CCG AGA CAT CTT
TG-30, a6 integrin antisense 50 -CAT GCT CAG TCT CTC CAC CA-30
(302 bp), all constructed based on the primer3 computer program
(www.genome.wi.mit.edu); a5 integrin sense 50 -CAT TTC CGA GTC
TGG GCC AA-30, a5 integrin antisense 50 -TGG AGG CTT GAG CTG
AGC TT-30 (324 bp); av integrin sense 50 -GTT GGG AGA TTA GAC
AGA GGA-30, av integrin antisense 50 -CAA AAC AGC CAG TAG CAA
CAA-30 (288 bp); b1 integrin sense 50 -TGT TCA GTG CAG AGC CTT
CA-30, b1 integrin antisense 50 -CCT CAT ACT TCG GAT TGA CC-30
(452 bp), all according to Tang et al (1995); TNF receptor-I sense 50 -ACC
AAG TGC CAC AAA GGA ACC-30, TNF receptor-I antisense 50 -CAC
ACG GTG TTC TGT TTC TCC-30 (320 bp), according to Huang et al
(1998); TNF receptor-II sense 50 -GAA TAC TAT GAC CAG ACA GCT
CAG ATG TGC-30, TNF receptor-II antisense 50 -TAT CCG TGG ATG
AAG TCG TGT TGG AGA ACG-30 (403 bp), according to Sato et al
(1997); IFN-g receptor sense 50 -TTT GCT GTATGC CGA GAT GGA-30,
IFN-g receptor antisense 50 -AGGAAA ATG GCTGGTATGACG-30 (592
bp), according toYanagida et al (1996); IL-6 receptor I sense 50 -CAT TGC
CAT TGT TCT GAG GTT C-30, IL-6 receptor I antisense 50 -AGT AGT
CTG TAT TGC TGA TGT C-3 (251 bp), according to Pth et al (1997);
glucocorticoid receptor-a sense 50 -ACA CAG GCT TCA GGTATC TT-
30, glucocorticoid receptor-a antisense 50 -ACT GCT TCT GTT GCC
AAG-30 (557 bp); glucocorticoid receptor-b sense 50 -ACA CAG GCT
TCA GGTATC TT-30, glucocorticoid receptor-b antisense 50 -CGC CAA
GAT TGT TGG GAT GA-30 (294 bp), both according to Dahia et al (1997).
The oligonucleotide primer set for IFN-a receptor (455 bp) was purchased
from Stratagene, La Jolla, CA. The lengths of the PCR products obtained
either corresponded to product lengths in the cited references or were in
accordance with the computer program.
Statistical analysis Signi¢cance levels were determined using the two-
tailed Student’s t test.
RESULTS
Integrin expression As shown previously (Krˇger-Krasagakes
et al, 1996) and as con¢rmed in this study on £uorescence-
activated cell sorter (FACS) analysis, 490% of HMC-1 cells
expressed CD29 (a1 integrin), CD49e (a5 integrin), and the
vitronectin receptor (ava5). More than 50% were positive for
CD49b (a2), CD49c (a3), and CD49d (a4), and between 25%
and 50% for CD51 (av) and CD49f (a6). In contrast, no binding
was observed for CD49a. In agreement with these ¢ndings,
HMC-1 cells expressed all but the a1 integrins at mRNA level,
with very marked bands for the a1, a4, a5, and av chains on
semiquantitative analysis (Fig 1). The lengths of the base pairs
corresponded to those published so far for the av, a5, and a1
primer pairs (Petermann et al, 1993) and the expected length for
a4 to the computer program.
Modulation of integrin expression Preincubation of HMC-1
cells with IL-6 enhanced integrin expression in the FACS analysis
with at least one of the three concentrations tested (Table I and
not shown), except for CD49c (a3) and CD49d (a4), where no
signi¢cant enhancement was observed.
In contrast, the other cytokines and the corticosteroids were
either inhibitory or showed no signi¢cant e¡ects on integrin
protein expression; TNF-a inhibited expression of all integrins
except for CD51 (av) and the vitronectin receptor (avb5), with
signi¢cance being observed for at least one of the three
concentrations tested (Table I and not shown). Inhibition by
TNF-a was most pronounced for CD49e (a5), even at the lowest
concentration tested (po0.001; data not shown).
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The inhibitory e¡ects of the IFNs and the corticosteroids were
quantitatively less pronounced than with TNF-a (Table I),
although signi¢cant inhibition was reached for most integrins at
protein level with at least one of the concentrations tested
(Table I and not shown). E¡ects induced by dexamethasone
were more marked than those observed on incubation with
hydrocortisone (not shown).
A modulatory e¡ect of cytokines and steroids on mast
cell integrins was also found by semiquantitative PCR analysis
(Fig 2 and Table II), con¢rming the data obtained at protein
level. For these studies, a1, av, and a5 integrins were selected as
they were most markedly expressed at mRNA level and could
therefore be best quanti¢ed (Fig 1). As shown in Fig 2, IL-6
always enhanced mRNA expression of integrins, whereas all
other molecules tested were inhibitory, with signi¢cance
(po0.05^0.001) being reached in each case for the values
obtained on densitometric analysis (Table II).
Adhesion assays Functional relevance of the modulatory
e¡ects of cytokines and steroids on integrin expression was
studied next in adhesion assays. Unstimulated and PMA-
stimulated adhesion of HMC-1 cells to ECM were comparable
to those observed by us before (Krˇger-Krasagakes et al, 1996).
IL-6 signi¢cantly enhanced adhesion to ¢bronectin, laminin,
and vitronectin, whereas TNF-a signi¢cantly inhibited adhe-
sion to ¢bronectin and laminin (Fig 3). Similarly, IFNs and
corticosteroids were inhibitory, although signi¢cance was
reached only for ¢bronectin with IFN-g, hydrocortisone,
and dexamethasone, and in addition for laminin with
dexamethasone.
Con¢rmation of integrin involvement in the adhesion process
enhanced by IL-6 was studied using blocking antibodies against
a1, ava5, and a5 integrins that have been shown to block HMC-1
cell adhesion to ¢bronectin and vitronectin, respectively. The
antibodies to a1 and a5 integrin reduced adhesion to ¢bronectin
in untreated and IL-6-treated cells by 83% and 85%, respectively.
For vitronectin, only PMA-stimulated cells were studied because
of very low adhesion of unstimulated HMC-1 cells to vitronectin
(Krˇger-Krasagakes et al, 1996). PMA-stimulated adhesion to
vitronectin of IL-6-treated HMC-1 cells was reduced from 78%
to 18% by avb5 blocking antibodies, and from 48% to 11% in
untreated cells. IL-6 e¡ects on laminin-mediated adhesion were
not studied in detail with blocking antibodies as HMC-1 cell
adhesion to laminin had been shown not to be integrin
mediated (Krˇger-Krasagakes et al, 1996).
Demonstration of cytokine and glucocorticoid receptors
Evidence for the mediation of the observed modulatory e¡ects
by speci¢c receptors was explored as well. At protein level, these
studies were conducted only for the TNF and IL-6 receptors as
no data for expression of these molecules on mast cells have
been published so far. As shown in Fig 4, TNF-RI and TNF-
RII as well as IL-6-RI were detected only at low level on the
surface of unstimulated HMC-1 cells, whereas expression of the
IL-6-RII was high.
In accordance with these data, mRNAs for each of the two
TNF and IL-6 receptors were detected on PCR analysis, as was
mRNA for glucocorticoid receptors (Fig 5).
DISCUSSION
In this study, several cytokines and corticosteroids have been
identi¢ed for the ¢rst time as modulators of integrin expression
and adhesion of human mast cells to ECM. In an earlier report
by Sperr et al (1992), no changes of HMC-1 cell integrin expres-
sion were noted after an incubation period of up to 24 h with
IL-3, IL-4, IL-8, IL-9, IL-10, and SCF. Because of these negative
data and as an impact of cytokines during in£ammation is ex-
pected to last for at least a few days, we extended here the incuba-
tion period to 48 h and studied cytokines not targeted in the
study by Sperr et al (1992). In another study, platelet-derived
growth factor, TNF-a, IFN-g, IL-1^IL-4, and endothelial
growth factors a and b failed to induce murine mast cell ECM
adhesion (Bianchine et al, 1992). In contrast, IL-1 has been re-
ported to cause a 5-fold increase of adherence of uterine human
mast cells to endothelial cells (Guo et al, 1992).
IL-6, an interleukin that induces acute phase proteins, is iden-
ti¢ed here as another molecule that enhances adhesion of mast
cells to ECM molecules by an upregulation of integrin mRNA
and protein expression of these cells. Speci¢city of this e¡ect is
underlined by blockage of HMC-1 binding to ¢bronectin, less
so to vitronectin, by antibodies against a1, a5, and ava5 integrins,
and by demonstration of the IL-6 receptor on HMC-1 cells.
Figure1. mRNA expression of integrins in HMC-1 cells (represen-
tative data from one of three experiments). Lane 1, 1 kb ladder; lane 2,
a1 integrin; lane 3, a2 integrin; lane 4, a3 integrin; lane 5, a4 integrin; lane 6,
a5 integrin; lane 7, a6 integrin; lane 8, av integrin; lane 9, b1 integrin; lane 10,
negative control (water); lane 11, 100 bp ladder.
Table I. Modulation of integrin expression by di¡erent cytokines and dexamethasone on FACS analysis
Antibody IL-6, 100 U per ml TNF-a, 1.5 ng per ml IFN-a, 100 U per ml IFN-g, 100 U per ml Dexamethasone, 109 M
CD29 þ 21.2 715.27  2.787 6.67 14.887 4.27n ^13.40711.34 23.477 3.71n
CD49b þ 3.337 1.81n ^13.127 10.59n ^19.80719.68 ^15.807 5.13n ^32.5 7 3.71n
CD49c þ 19.87716.67 ^33.45712.97n ^5.24724.24 ^7.50710.60 ^41.77737.11
CD49d þ 18.7 711.66 ^32.1 715.79n ^31.12713.46n ^19.77727.69 ^34.20748.09
CD49e þ 18.7 712.42n ^57.637 8.5n ^16.13726.55 ^15.677 14.72 ^5.057 1.91
CD49f þ 8.8 7 1.70n ^29.95716.48 ^15.607 2.00 ^11.15744.61 ^36.75711.67n
CD51 þ 39.1 7 9.26n ^13.7 723.79 ^11.62737.06 ^1.057 7.85 ^37.107 2.00n
ava5 þ 29.88712.43
n ^18.62724.56 ^16.48728.30 ^11.15744.62 ^56.3 720.07n
Percentage change in mean £uorescence intensity (mean7SD) was calculated from values obtained during ¢ve di¡erent FACS analyses.
nStatistical signi¢cance at po0.05 using the paired t test.
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IL-6 has in the past been reported to enhance di¡erentiation
and antiapoptotic e¡ects of umbilical-cord-blood-derived mast
cell precursors in vitro (Saito et al, 1995; Oskeritzian et al, 1999).
Furthermore, IL-6 has been reported to increase integrin
expression and/or adhesion to ECM of rabbit cornea epithelial
and human natural killer cells (Rabinowich et al, 1993; Ohashi
et al, 1995) and adhesion of lymphocytes to endothelial cells
(Watson et al, 1996). As HMC-1 cells also produce IL-6 even
Figure 2. mRNA analysis of integrins after exposure of mast cells to di¡erent cytokines (representative data from one of ¢ve experiments).
Table II. Densitometric analysis of integrin mRNA expression in
HMC-1 cells after preincubation with cytokines and corticosteroids
Cytokine or corticosteroid a1 integrin av integrin a5 integrin
IL-6 (100 U per ml) þ 34.63710.07nnn þ 26.3674.51nnn þ 48.04718.53n
TNF-a (1.5 ng per ml) 34.68721.06n 45.1077.63nn 34.017 5.96nnn
IFN-a (100 U per ml) 28.427 5.49nnn 16.4473.65n 31.887 5.26nnn
IFN-g (100 U per ml) 40.75712.43nn 53.2378.76nn 58.787 3.74nnn
Hydrocortisone (107 M) 32.60716.97nn 36.5679.09nn 22.327 8.02nn
Dexamethasone (109 M) 47.70705.70nnn 51.6275.41nnn 30.287 9.65nn
Data were calculated as percentage change from the mean a-actin values set at 100% and are expressed as mean7SD. npo0.05; nnpo0.01; nnnpo0.001.
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during adhesion to ECM, as reported before (Krˇger-Krasagakes
et al, 1996; 1999), an autocrine stimulation of the process of adhesion
may be operative in vivo. In view of all the data provided here and
in the literature, it is conceivable that IL-6 plays an important role
in mast cell accumulation and survival at sites of in£ammation.
SCF and FceRI are additional molecules reported to enhance
adhesion of mast cells to ECM (Thompson et al, 1990; Bianchine
et al, 1992). They could not be compared to IL-6 e¡ects in this
study as HMC-1 cells fail to respond to SCF due to mutations
of its c-kit receptor, and FceRI is not at all or only rarely func-
tionally expressed on HMC-1 cells (Butter¢eld et al, 1988; Furitsu
et al, 1993; Hamann et al, 1994;Weber et al, 1996). The observation
that IL-6 a¡ects integrin mRNA and protein expression of
HMC-1 cells whereas FceRI-induced e¡ects have been shown to
be only associated with increased integrin receptor avidity for
binding to ECM molecules (Dastych et al, 2001) underlines
the potential importance of IL-6 in mast-cell-associated
in£ammation.
In contrast to the ¢ndings with IL-6, other cytokines like
TNF-a, IFN-a, and IFN-g as well as corticosteroids had no or
even inhibitory e¡ects on mast cell integrin expression and adhe-
sion to ECM. As also observed with IL-6, only minor e¡ects on
cell proliferation (unpublished observation) and receptor expre-
ssion of HMC-1 cells speak against nonspeci¢c changes induced
by these molecules. This is in agreement with ¢ndings on lower
expression of integrins in other models and cell systems, and
with lower mast cell numbers on coculture of mast cells with
endothelial cells in the presence of TNF-a (De¢lippi et al, 1991;
1992; Chou et al, 1996). Results along this same line have been
reported for IFN-g (Wills et al, 1999). IFN-a and IFN-g have
furthermore been shown to be useful in the treatment of some
patients with mastocytosis and atopic dermatitis, representative
diseases with an associated increase of mast cells (Torrelo et al,
1992; Hartmann and Henz, 2001). As TNF-a is produced abun-
dantly by mast cells, including HMC-1 cells (M˛ller et al, 1998),
the question arises whether the inhibitory e¡ects of this molecule
or the enhancement of integrin expression induced by IL-6 pre-
dominates at tissue sites and which one of the cytokines is more
important in determining the fate of mast cells in di¡erent
disease states.
Corticosteroid treatment has long been known to cause a
reversible decrease of mast cell numbers in normal and diseased
tissue (e.g., Lehmann et al, 1983). HMC-1 cells express receptors
not only for corticosteroids but also for other members of the
nuclear receptor family like vitamin A and D, and in fact retinoic
acid also downregulates integrin expression on HMC-1 cells, like
dexamethasone (Henz et al, 2001). The corticosteroid-induced
reduction of integrin expression at mRNA and protein level, as
observed here, is thus in agreement with these ¢ndings. Mecha-
nisms like induction of apoptosis and reduction of cytokine
Figure 3. Modulation of mast cell adhesion to matrix proteins by cytokines and corticosteroids. Data show the mean7SD of the percentage
change of adhesion in comparison to untreated control cells, out of ¢ve di¡erent experiments. npo0.05 and nnpo0.001, using the paired t test.
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secretion by mast cells and surrounding tissue cells, however,
may also be operative during corticoid-induced mast cell reduc-
tion in vivo (Lippert et al, 1996; Zhang et al, 2000).
An interesting question regarding the possible mechanisms
governing mast cell ECM adhesion is raised by the observation
that di¡erent integrins are not equally a¡ected by cytokines and
corticosteroids. Whereas more potent corticosteroids like dexa-
methasone downmodulate more integrins than naturally occur-
ring hydrocortisone, a clear dose^response relationship could not
be established with any of the molecules studied here. In the
past, spontaneous as well as PMA-, SCF-, and FceRI-mediated
enhancement of mast cell adhesion, calcium dependence, and PI
3-kinase mediated intracellular events have been demonstrated
(Columbo et al, 1995; Dastych and Metcalfe, 1995; Krˇger-Krasa-
gakes et al, 1996; Kinashi et al, 1999), but mechanisms involved in
the modulation of mast cell integrin expression and ECM adhe-
sion by di¡erent cytokines and by corticosteroids, as shown here,
are still entirely unknown. Clari¢cation of these and of addi-
Figure 4. FACS analysis, demonstrating expression of TNF receptors I and II as well as of IL-6 receptors I and II on unstimulated HMC-1
cells. Data show one of two representative experiments.
Figure 5. mRNA expression of the receptors shown in Fig 4 and in addition of glucocorticoid receptors on unstimulated HMC-1 cells.
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tional aspects of mast cell integrin expression and ECM adhesion
is an important challenge for future investigations into mechan-
isms regulating mast cell tra⁄cking and function at sites of
in£ammation.
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